Mustang Bio, a New York-headquartered clinical-stage biopharmaceutical company and a subsidiary of the biopharmaceutical company, Fortress Biotech, has entered into a lease agreement with the UMass Medicine Science Park in Worcester, Massachusetts, for a manufacturing facility to support the development and commercialization of the company’s CAR-T product candidates.

The facility is expected to be operational for producing personalized CAR-T therapies in 2018. Mustang anticipates initially building cell-processing capabilities to support its lead CAR-T product candidates, now in Phase I development, MB-101 for treating brain cancer and MB-102 for treating acute myeloid leukemia. Mustang is partnered with the City of Hope National Medical Center and the Fred Hutchinson Cancer Research Center for these CAR-T therapies.

Source: Mustang Bio